Stay updated on CaBozantinib in Advanced Renal Cell Carcinoma Clinical Trial

Sign up to get notified when there's something new on the CaBozantinib in Advanced Renal Cell Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the CaBozantinib in Advanced Renal Cell Carcinoma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:13:23.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the progression free survival (PFS) assessment of cabozantinib in patients with advanced or unresectable Renal Cell Carcinoma pretreated with one immunotherapy checkpoint inhibitor.
    Difference
    0.1%
    Check dated 2024-06-06T14:19:45.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying requirements such as previous treatments, health conditions, and other medical criteria necessary for inclusion in the study.
    Difference
    37%
    Check dated 2024-05-22T21:12:08.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:56:36.000Z thumbnail image

Stay in the know with updates to CaBozantinib in Advanced Renal Cell Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the CaBozantinib in Advanced Renal Cell Carcinoma Clinical Trial page.